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ABSTRACT
USE OF THE BIONESS L300® FUNCTIONAL ELECTRICAL STIMULATOR
IN ACUTE STROKE REHABILITATION
by
Christine Flanigan
Colleen M. Martinez
Beth N. Terranova
Nicholas Wildi

Purpose. Over 150,000 people in the U.S. every year experience foot drop following a stroke,
slowing their ambulation and increasing their falls risk. We explore whether the use of
functional electrical stimulation (FES) to the common fibular nerve during acute rehabilitation
can maximize ambulation gains. Methods. Five in-patients admitted at Burke Rehabilitation
Hospital experiencing foot drop participated. While receiving conventional physical therapy,
four subjects wore the Bioness L300® device, and one subject used an elastic figure-8 wrapped
elastic bandage. Gait parameters were evaluated at initial evaluation, an intermittent evaluation,
and discharge. Results. During their stay, subjects significantly improved in gait velocity,
percent of gait cycle in single-leg-stance for the involved lower extremity, percent of gait cycle
in stance time for the involved lower extremity, and other gait-related variables. Conclusion.
Future research is needed to confirm FES as a more helpful adjunct than an elastic wrap during
acute rehabilitation.
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Each year, stroke affects approximately 795,000 people in the United States, and
approximately 15 million people worldwide (Bethoux et al., 2015). Approximately 75% of
stroke victims survive, and the cost of medical care for these individuals is high at an estimated
$3.6 billion dollars each year (Bethoux et al., 2015). Given the incredibly high costs, it is
imperative that clinicians find the most efficient and effective rehabilitative methods to return
these individuals to functional mobility as quickly as possible.
One of the primary problems facing therapists working with stroke patients is foot drop, a
condition in which the individual has difficulty dorsiflexing the foot due to reduced or entirely
absent stimulation of the deep fibular nerve. Foot drop affects an estimated 20% of stroke
survivors, or approximately 159,000 people in the U.S. each year (Bethoux et al., 2015). The
inability or weakened ability to dorsiflex the foot leads to an increased falls risk and poor gait
quality because the individual will either drag the foot along the floor during swing phase, or
circumduct or vault up on their other leg at the hip to clear the involved foot from the ground.
These altered gait patterns lead to significantly slower gait speeds and increased risk of falls
(Sackley et al., 2009; Weerdesteyn, de Niet, van Duijnhoven, Hanneke, & Geurts, 2008).
Given the high prevalence of foot drop in stroke populations, and its impact on gait
patterns, special consideration should be given to developing the most effective techniques to
address foot drop while rehabilitating stroke survivors. The treatment of foot drop varies
depending on therapist preference and the patient’s degree of disability.
In the initial stages of stroke recovery, a therapist may use a temporary dorsiflexion
assistive device, such as a figure-8 wrapped elastic bandage, to wrap the lower leg and foot and
maintain it in a dorsiflexed position. This position will prevent foot drop and toe drag during
walking, transfers, and stair climbing. Later in the recovery process, the patient may be fitted for

1

an anide-foot orthosis (AFO), one of the most common long-term treatment methods for foot
drop (van Swigchem, van Duijnhoven, den Boer, Geurts, & Weerdesteyn, 2012). The AFO is a
plastic splint that covers the posterior aspect of the leg up to below the knee and keeps the anicle
in neutral dorsiflexion throughout gait (van Swigchem et al., 2012). Although use of a figure-8
wrapped elastic bandage or AFO can help create a more functional gait, these treatment methods
do not allow free ankle movement, can be bulky to wear, and do not allow for activation of both
dorsiflexors and plantarfiexors during ambulation to help normalize gait. (Ring, Treger,
Gruendlinger & Flausdorff, 2009; Singh, Singh, Wangjam, Kiba & Nandabir, 2001; Taylor et al.,
1999). Because of the bulky design of some AFO devices, and the restriction of movement they
create, patient compliance in wearing the device is often a concern (Everaert et al. 2013; Taylor
et al., 1999).
An alternative intervention to the use of wrap bandages or an AFO, is the use of a device
that provides functional electrical stimulation (FES) during gait. FES uses a non-noxious
electrical stimulus to activate the dorsiflexors and evertors of the anicle to produce smooth
dorsiflexion during the early stance and swing phases of gait (van Swigchem et al., 2012). FES
also allows plantarfiexion during toe-off, resulting in a smooth toe-off without the restriction of
movement by an AFO, which would keep the foot in a dorsiflexed position throughout gait. In
plain terms, FES imitates the activation of muscle in a healthy individual.
FES, and electrical stimulation in general, has been shown to increase muscle strength
and the maximum voluntary contraction, and reduce spasticity (Sabut, Sikdar, Kumar, &
Mahadevappa, 2011; Yan, Hui-Chan, & Li, 2005). FES has also been shown to increase gait
speed and the number of steps taken, without increasing the effort expended by the patient
(Morone, Fusco, DiCapua, Coiro, & Pratesi, 2012; Stein et al., 2010; Everaert, Thompson,
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Chong, & Stein, 2010). When used long term, FES has been shown to improve a patient’s
functional ambulation and ability to avoid obstacles (van Swigchem et al., 2012). When paired
with traditional physical therapy, FES significantly improves walking ability and motor control
over conventional physical therapy alone (Sabut, Sikdar, Mondal, Kumar, & Mahadevappa,
2010). Patients also tend to feel that FES helps them with gait, and thus may help improve
compliance (Taylor et al., 1999). Thus, FES may provide an addition to physical therapy
treatment that is beneficial in producing a more functional gait profile (Everaert et al., 2013).
Many researchers hypothesized that FES may also improve corticospinal connections
because it actively stimulates the nerve (Everaert et al., 2013; Sabut et al., 2011; Everaert et al.,
2010; Stein et aL, 2010; Sheffler, Hennessey, Naples, & Chae, 2007; Taylor et al., 1999). Studies
have found that the gait parameters of individuals who have used the device continue to improve
when the device is off (Everaert et al., 2010; Stein et al., 2010). Everaert and colleagues (2010)
compared the effect of FES on gait speed of individuals with foot drop as a result of non
progressive neurological conditions (stroke) versus progressive neurological conditions (multiple
sclerosis). The authors looked at gait speed both with the device on and the device off The
authors found a significant increase in gait speed in both groups with the device on and with the
device off, suggesting an improvement in corticospinal connections from FES. These findings
suggest that use of FES in rehabilitation may be preferable to the use of an AFO, which does not
offer the same lingering improvements in gait parameters when walking without the device.
A problem with many of the studies touting the positive effects of FES, however, is that
many of the studies did not have a control group and did not compare improvements made using
an FES device to improvements made using more conventional, and cheaper, interventions such
as a figure-8 wrapped elastic bandage. In the studies that included a non-FES wearing control
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group, the definition of control parameters were often not clear, stating only that “conventional”
therapy was provided without defining what “conventional” therapy entailed (Sabut et al., 2011).
Of the studies that did use such a clearly-defined control, the findings regarding the benefits of
FES over an AFO have been mixed; and most involve individuals who are chronic stroke
survivors, rather than those that are in the acute stage of recovery. Some studies have found
indications that FES may improve gait speed as compared to an AFO (Morone et al., 2012; van
Swigchem et al., 2012), while other studies found no statistical difference between the use of an
AFO and an FES device on gait speed after stroke recovery (Everaert et al., 2013; van
Swigchem, Vloothuis, den Boer, Weerdesteyn, & Geurts, 2010; Ring et aL, 2009; Sheffler,
Hennessey, Naples, & Chae, 2006).
Morone et al., (2012) found that during the subacute phase of stroke recovery, patients
that used the WalkAideTM FES device during therapy had a significantly increased gait speed as
compared to the control. Similarly, van Swigchem et al., (2012), found that individuals with
chronic stroke who used FES had a significantly improved ability to avoid obstacles as compared
to individuals wearing an AFO, which is indicative of a more functional gait.
On the other hand, many studies have found no significant difference in the gait speed
between stroke patients that use an FES device and those that use an AFO (Bethoux et al., 2015;
Bethoux et al. 2014; Everaert et al., 2013; van Swigchem et al., 2010; Ring et al., 2009; Sheffler
et al., 2006). One of these studies even found that an AFO has a better immediate orthotic effect
than FES (Everaert et al., 2013). Everaert et al. (2013) designed a twelve-week study that
compared the use of an AFO to FES (the WalkAideTM Device) for individuals with foot drop
who were less than one year post-stroke. Participants were assigned to three groups: group one
used the WalkAideTM FES device for six weeks followed by an AFO for the next six weeks;
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group two used an AFO for six weeks, followed by the WalkAideTM device for the next six
weeks; and group three used the AFO for all twelve weeks. The participants’ gait speed was
measured while performing a four-minute figure-8 walk and while walking 10 meters. The
energy cost of the participants was also measured. There was no statistical difference in
participants’ gait speed when wearing either the AFO or the WalkAideTM device, but the AFO
had a significantly improved orthotic effect. There was no significant difference in the energy
cost expended.
Other studies have shown similar results (Everaert et al., 2013; van Swigchem et al.,
2010; Ring et al., 2009; Sheffler et al., 2006), including two recent large-scale studies involving
chronic stroke survivors (Bethoux et al., 2015; Bethoux et aL, 2014). Bethoux et al., (2014),
conducted a multicenter randomized trial involving 495 individuals with foot drop who were at
least 6 months post-stroke. Bethoux et al., (2014), randomly assigned participants to wear either
FES or an AFO for 6 months. The study found that both groups made significant gains in their
gait parameters, but that there was no significant difference between those that wore the FES and
those that wore an AFO (Bethoux et al., 2014). Bethoux et al., (2015) then followed 384 of these
participants 12 months afler the commencement of the study and again found no significant
difference between those that used FES and those that used an AFO. Everaert et al. (2013)
posited that one of the reasons there is little difference between the devices may be because the
AFO reliably maintains the individual’s foot in a dorsiflexed position allowing for an immediate
stabilizing effect comparable to that of an FES device.
Notwithstanding the contradicting evidence, FES poses several possible advantages over
the use of an AFO. One such advantage is the possibility that it can help reestablish andlor
strengthen the corticospinal connections as discussed above (Everaert et al., 2013). Another
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possible advantage is that studies have shown that more patients report a favorable experience
with the FES device, than with an AFO (Kiuding et al., 2013; Everaert et al., 2013; van
Swigchem et al., 2010). Patients preferred the FES device over the AFO based on the following
factors: effort, stability, safety, quality of gait, distance walked, comfort, ankle mobility, and
appearance (van Swigchem et al., 2010). Patients wearing either device reported feeling safe,
but patients who wore an FES device reported feeling safer when walking without the FES
device as compared to AFO users walking without the AFO (Everaert et al., 2013). Additionally,
patients who have worn both an AFO and an FES device indicate a preference for wearing the
FES device over the AFO (Everaert et al., 2013; vanSwigchem et al., 2010; Bulley, Shiels,
Wilkie, & Salisbury, 2011). This preference may help to increase patient compliance with
wearing the device in the future, which can be a problem for AFO users (Everaert et al. 2013;
Taylor et aL, 1999).
Many studies investigating the efficacy of FES have focused on chronic stroke survivors
in order to eliminate the possible confounding factor that gait improvements are due to
spontaneous recovery (Everaert et al., 2010; Kottink et al., 2008). FES, however, may also offer
additional benefits during the acute phase of recovery. It has been shown that repetition and
progression of task specific exercises, such as gait training, even without FES, lead to greater
functional outcomes during the acute phase of stroke rehabilitation, but that this effect is lost
after 90 days (Rose et al., 2011). FES may be an important adjunct to therapy during this time.
The benefits of FES, such as increased gait speed, muscle strength and voluntary muscle
contraction and reduced spasticity, may lead to improved overall recovery in the acute phase by
allowing the therapist to accomplish more gait training and repetition during a therapy
session. When used for training of the tibialis anterior muscle, FES treatment helped acute
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stroke patients walk two to three days earlier than control subjects and increased the probability
they would be discharged home from the hospital (Yan et al., 2005). Other studies in acute
stroke populations have also found better outcomes in ambulation, flmctional activity, and
decreased length of stay with the use of FES therapy (Dunning, Black, Harrison, McBride, &
Israel, 2009). Studies of the use of FES during the acute stages of stroke recovery, however, are
few and have been limited in their scope.
Yan et al. (2005) examined the use of FES during acute stroke recovery and found less
spasticity together with significant improvement in a patient’s ability to walk (as measured by
the number of days until ambulation) when compared to patients who received placebo FES, but
did not compare FES to conventional therapy using a temporary dorsiflexion assist device.
Dunning et al. (2009) studied the effectiveness of FES on two patients in the acute stages of
stroke recovery. Dunning et al. (2009) found that the first patient, who had only mild weakness
on the involved side (4/5 dorsiflexion strength with heel support and 2/5 dorsiflexion strength
without heel support on manual muscle test) showed dramatic improvement until the device was
no longer needed, while the second patient, who had severe weakness on the involved side (0/5
dorsiflexion strength) had difficulty achieving a dorsiflexion contraction with the device, and had
inconsistent results. While the second subject was able to improve her dorsiflexion strength
during the study from 0/5 to 3-/5, she rapidly fatigued and continued to experience foot drop
during gait at the time of her discharge four weeks later. This study, however, was limited in the
number of participants and its application is therefore very limited. No study has, as of yet,
sought evidence comparing the use of FES to a temporary dorsiflexion assist device, such as a
figure-8 wrapped elastic bandage or AFO, in the acute phase of stroke recovery to determine if
more functional ambulation gains are made.
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The purpose of this study was to determine if FES combined with conventional physical
therapy used during the acute phase of stroke recovery improves gait parameters when compared
to use of a temporary dorsiflexion assist device and conventional physical therapy. The
temporary dorsiflexion assists were figure-8 wrapped elastic bandage wraps or AFO. The
Bioness L300® was the FES device used in this study. Our research questionnaires asked
whether patients and their treating physical therapists found any benefit of the FES when
compared to the figure-8 wrapped elastic bandage wrap or AFO. In order to successifilly use
FES in acute care rehabilitation, the device must be easy to don and doff; the device settings
must be easy to calibrate; and the initial set-up and subsequent device adjustments must not be
time-consuming to the therapist. If these parameters are met, we hypothesize that the device
may be easily incorporated into a patient’s acute care rehabilitation and lead to greater therapist
satisfaction.
In addition, for use of an FES device to be feasible during in-patient rehabilitation, it
must generate sufficient patient satisfaction to ensure patient compliance with wearing the
device. If the device is too uncomfortable or bulky, or makes the patient feel unstable, then it
may hinder, rather than help, rehabilitation.
Our null hypothesis is that no difference in either the gait parameters or the patient and
therapist preferences will exist. Our first alternate hypothesis is that a surface FES device, such
as the Bioness L300®, will improve gait parameters as compared to a temporary assist device
during acute rehabilitation. Our second alternative hypothesis is that the therapist will like using
the device, and feel that they can accomplish more during a treatment session, leading to
improved recovery. Our third alternative hypothesis is that this device will be preferred by the
patient and their physical therapist over the traditional AFO. Evidence of the usefhlness of this
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device in an acute care setting may create a precedent for new treatment protocols for stroke
rehabilitation involving FES therapy.

9

Method
Design
We used a prospective, within-subject design to determine if the FES intervention
affected gait parameters during participants’ inpatient rehabilitation stay. Originally, a betweensubject component was proposed to isolate the effect of group assignment, (FES+ conventional
therapy, or temporary assist device

+

conventional therapy). However, the randomization (coin

toss) technique failed to yield enough control subjects and enrollment was lower than
anticipated. A prospective observational survey method was used to determine patient and
therapist satisfaction with both treatment types. The study took place at Burke Rehabilitation
Hospital (BRH) and was approved by the Institutional Review Board of BRH as well as the
Human Research Participation Program of Hunter College.
Subjects
Participants were recruited from an in-patient acute neurological rehabilitation floor at
BRH. To be eligible for the study, participants must have suffered a stroke less than four weeks
prior to their admission to BRH and presented with foot drop upon their initial physical therapy
evaluation. The pool of eligible subjects were divided randomly amongst the control and
intervention groups, by method of a coin toss. Participation in this study, and assignment to
either group, did not interfere with standard patient care as both groups received conventional
physical therapy.
A total of six participants were enrolled in this study, and numbered 1-6. Of this number,
one subject was consented but was found to have a neuropathy, which prohibited the use of the
FES. Of the remaining five participants, one was assigned to the control group via coin toss and
received treatment with only figure-8 wrapped elastic bandage. The remaining four participants
10

were all assigned to the FES group as a result of the coin toss. The disability of the four
experimental participants ranged from minimal impairment to severe.
All individuals who had been admitted into the in-patient program at BRH after suffering
a stroke within four weeks prior to admission and who exhibited foot drop during gait were
considered for participation in this study. Inclusion criteria required all subjects to be able to
achieve at least a neutral (or greater) degree of passive dorsiflexion, and be able to ambulate at
least 10 meters either independently or with assistance prior to the intervention. These measures
were assessed during the patient’s initial evaluation, which was completed by the treating
physical therapist. Participants were all English-speaking.
Exclusion criteria included individuals with demand-type cardiac pacemakers,
defibrillators, or other similar electric cardiac stiniulators; individuals with metastatic cancer;
individuals presenting with acute fracture or dislocation of the lower leg; individuals with weight
bearing or range of motion restrictions of the lower leg; individuals presenting with active
cellulitis or infection of the lower leg to be stimulated; individuals presenting with a lower
extremity wound prohibiting use of the Bioness L300® device; individuals who were medically
unstable or are unable to participate in therapy; those with a calf circumference greater than 20
inches; and, individuals with inadequate language fimction to understand and respond
appropriately to one-step commands. Exclusion criteria were based on precautions,
contraindications, and regulations mandated by the Bioness® company. Based on previous
protocols using the Bioness® device, inability to comprehend one-step commands was
considered a reason for exclusion, specifically for safety purposes (Tong, Ng, Li & So, 2006).
Patients were first evaluated by a BRH physical therapist. After this initial evaluation,
the lead investigator reviewed the patient’s information. If all the requirements of subject
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inclusion and exclusion criteria were met, patients were invited to participate as research
subjects, and patients providing informed consent were admitted into the study. Patients were
then assigned to either the experiment or control group based on a coin toss. Research subjects
were assigned a unique identi~’ing code and for subjects assigned to the experimental group, a
physician prescription for use of the Bioness® device was obtained. Figure 1 summarizes
subject assignment.
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Patient evaluated by physical therapist
,~,

Patient chart evaluated by lead—investigator
if all inclusion and exclusion criteria are met

no

Patient not considered for research

[

Patient consent obtained

~1~

Coin toss determines group assignment
if

tails

heads

Patient assigned to experimental group

1

Patient assigned to control group

Patient paired with unique identifying code
if assigned to experimental

group

Physician prescription for use of device obtained

Figure 1. Preparing Subjects and Group Assignment. This graphic demonstrates how subjects
were recruited and assigned.
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Intervention
Both research groups received treatment sessions of approximately the same duration and
frequency. Participants assigned to the control group received standard therapy (6 days per
week) as normally provided at BRH and used either a figure-8 wrapped elastic bandage or an
AFO for passive dorsiflexion of the ankle-foot during gait training.
Subjects assigned to the experimental group received standard therapy (6 days per week)
plus training with the Bioness L300® device for approximately three treatment days per week.
Therapists using the Bioness L300® device followed manufacturer guidelines and were trained
how to fit, program, and best utilize the device. On days where the experimental group was not
receiving treatment with the Bioness L300® device, a figure-8 wrapped elastic bandage or AFO
was utilized as an alternate dorsiflexion device.
Data Collection
Once patients were accepted in the study, information from their electronic medical
record and their initial therapy session were retrospectively retrieved and inserted into a database
that only used patients’ unique identif~’ing codes. The following information was obtained: age;
gender; diagnosis and lesion type; date of incident; endurance ability of patient and gait velocity
at initial evaluation, as measured with the 10-Meter Walk Test; spasticity at initial evaluation, as
measured with the Modified Ashworth Scale, mobility as measured by Timed Up-and-Go, and
balance as measured by Berg Balance Scale. Repeated outcome measurements for Zeno
Electronic Walkway with PKMAS software variables, 10-Meter Walk Test, Timed Up-and
Go, Berg Balance Scale, and the Modified Ashworth Scale were obtained for each patient during
weekly and discharge re-evaluations. Data were thus collected for individual patient subjects
along the schedule presented in Table 1.
14

Table 1.
Data Collection Schedule
Event/Day

Information and Measurements Obtained

Patient enrolled

Retrospective data from electronic medical record on initial evaluation:

in study

Weekly outcome

•

Patient name (assigned to code)

•

Research group assignment

•

Age

•

Gender

•

Diagnosis and Lesion Type

•

Date of incident

•

10-Meter Walk Test

•

Berg Balance Scale

•

Modified Ashworth Scale

•

Timed Up-and-Go

Repeated outcome measurements for:

measurements

•

Zeno Electronic Walkway variables

(captured every 7

•

10-Meter Walk Test

days)

•

Berg Balance Scale

•

Modified Ashworth Scale

•

Timed Up-and-Go

1 week pre-

Survey instmments administered to patients or provided for completion to

discharge

therapists:

Discharge
evaluation

•

Patient Survey Instrument

•

Therapist Survey Instrument

Repeated outcome measurements for:
•

Zeno Electronic Walkway variables

•

10-Meter Walk Test

•

Berg Balance Scale

•

Modified Ashworth Scale

•

Timed Up-and-Go
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Administering Patient and Therapist Surveys
Patient survey instruments were administered approximately one week before a patient’s
anticipated discharge from BRH. For the purposes of this study, if a subject was unable to speak
or write their responses, a proxy who had been present for approximately 50% or more of
therapy sessions was permitted to complete the survey. Proxy respondents have been utilized in
prior studies involving patient satisfaction with acute stroke care (Asplund et al., 2009; Reker et
al., 2002). Patients unable to speak or write their responses that were without an eligible proxy
were not asked to complete the survey instrument.
Primary attending physical therapists were also surveyed for their satisfaction with
dorsiflexion assist devices (figure-8 wrapped elastic bandage, AFO, or Bioness L300®) as
pertaining to specific patients. They were asked to complete a survey instrument for each patient
for whom they acted as the primary therapist. Therapist survey instruments were required to be
completed within one week of patient discharge from our experiment and only required a
researcher to provide the survey instrument, but not actively administer it. All survey
instruments utilized unique identifying codes and no patient names.
Materials
Bioness L300®’. The Bioness L300® is a Functional Electrical Stimulation (FES)
device. By means of a heel sensor in the user’s shoe, the FES providing cuff wonjust below the
user’s knee, administers an electrical impulse in sync with the user’s particular gait pattern. The
electrical impulse stimulates the common fibular nerve, which, in turn, activates the tibialis
anterior muscle and fibularis muscles and initiates ankle dorsiflexion and eversion. The
dorsiflexion allows clearance of the participant’s foot from the ground during swing phase of

Manufactured by Bioness, Inc.
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gait, thus avoiding toe drag or foot drop. The impulse was adjusted to each participant to be
strong enough to produce a contraction of the tibialis anterior without creating a noxious or
painful sensation.
The cuff worn by the user is made of a light-weight material meant to be breathable and
comfortable. The Bioness L300® has been marketed as a device for chronic stroke patients, with
a comfortable design to be worn for many hours a day as an assistive device. In our research, the
device was worn for 15-30 minutes at a time, three times a week, during gait training of regularly
scheduled therapy sessions. This device has been shown to be comfortable in a chronic stroke
population for full-day wear (Everaert et al., 2013; van Swigchem et al.,

2010; Bulley et al.,

2011). Patient comfort with the device in acute rehabilitation was assessed with the patient
satisfaction survey.
Zeno Electronic Walkway with PKMAS Software. Subjects’ improvements were
measured weekly using the Zeno Electronic Walkway with PKMAS Software system2. The
system requires the subject to walk along a 10-meter mat and provides an animated mapping of
the subject’s gait pattern. The recorded gait pattern is then analyzed using the PKMAS
software2, and all temporal and spatial parameters of gait are computed and recorded. The
technology of the Zeno Electronic Walkway with PKMAS Software was developed from that of
the GAITRite® walkway2. Research has shown that the PKMAS software produces variables
that can be used interchangeably with those derived from the GAITRite® (Egerton, Thingstad, &
Helbostad, 2014). The GAITRite® is a reliable tool, and is particularly precise when measuring
cadence (Vartiainen, Savolainen & Alaranta, 2009). Previous research has shown that the
GAITRite® measurements are valid, and test-retest reliability is strong (Greene et al., 2012).

2

Manufactured by ProtoKinetics, Havertowri, PA.
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In this study, data were used by the investigators to track improvements in gait
kinematics. The Zeno Walkway provides quantitative expressions of velocity, cadence, and step
length, which measures can be used as indicators of neurological recovery post stroke
(Vartiainen et al., 2009).
To use the walkway, the patient ambulated with an appropriate assistive device and
therapist guarding for the length of the mat. Two Zeno Electronic Walkway with PKMAS
Software trials were completed at the conclusion of every therapy week, one with the device on
and one with it off (using a figure-8 wrapped elastic bandage as needed). The data collected were
only at “steady state” in the middle 50% of the mat to reduce error of acceleration and
deceleration at the beginning and end of the mat.
Preparing and administering the Zeno Electronic Walkway with PKMAS Software
testing is simple, and it has been shown to provide precise gait measurements in brain-injured
populations (Vartiainen et al., 2009). Cheng, Yang, Cheng, Lin & Wang, (2010) successfully
used the GAITRite® when assessing the effects of FES on chronic stroke patients who
experienced foot drop and plantarfiexor spasticity. That study investigated an intervention
similar to our use of the Bioness L300® device, measured similar outcomes as our research, and
studied a sub-acute stroke population that were at least three months post-stroke, which is closer
in similarity to our sample than the studies on chronic stroke survivors that were greater than 1
year post-stroke. This previous research highlighted the GAITRite® as a feasible and convenient
measure to use while doing research in a clinical setting.
Outcome Measures
All outcome measures used, with the exception of the satisfaction surveys, had been
validated, and found reliable by previous research. Although different therapists administered
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the measurement tests used in this research, all information was gathered in a standardized
method, and all tests used have strong inter-rater reliability and test-retest reliability, making
them ideal tools for research in a clinical setting.
10-Meter Walk Test. The 10-Meter Walk Test (10-MWT) has been approved for use in
several studies as a meaningful outcome measure when looking at gait in stroke patients, both
acute and chronic (Vartiainen et al., 2009; Laufer, Ring, Sprecher, & Hausdorif, 2009).
Vartiainen et al. (2009) used a modified version of the 10-MWT, analogous to a primitive
GAITRite® system, using pens attached to the subjects shoes to make comparisons to the
modem day GAITRite® of the subjects’ velocity, cadence, and right and left step length. The
two methods showed significant levels of agreement, when measuring gait in brain injured
(stroke or traumatic brain injury) patients. A simpler form of the 10-MWT was used in this
study, similar to that used in Laufer et al. (2009) as a second reliable method of calculating gait
velocity. The simple version of the I 0-MWT uses a stopwatch to measure the time it takes
subjects to walk across a 10 meter long level, marked surface. The 10 meters are measured
within 14 meters of level surface in order to avoid skewed results that include initial take-off and
stopping time. Calculations taken from the 1 0-MWT provided a record of mid-route gait
velocity, as initiation and termination speeds are not included.
For this study, the 1 0-MWT was used as part of the initial evaluation in order to
determine if inclusion criteria were met. The 1 0-MWT is part of the standard evaluation
completed by staff at BRH, and allowed the evaluating therapists to determine if the potential
subject would be able to ambulate along the 10-meter mat of the Zeno Electronic Walkway used
in this study. The 1 0-MWT was repeated during progress evaluations, as is standard at
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BRH. The simplicity of this test helped to avoid the potential novelty effect the Zeno Walkway
with PKMAS Software testing conditions may have on the participant.
Berg Balance Scale (BBS). The Berg Balance Scale (BBS) has repeatedly been used in
patients post-stroke to quantify functional improvements. Tong et al. (2006) described the BBS
as having “excellent interrater and intrarater reliability for elderly subjects, and for subjects with
acute stroke” (p.1299).
The BBS is regularly used weekly at BRH to monitor improvements in their patients. The
BBS requires two chairs, one with arm rests and one without, a step, a 15- meter walkway, and a
timing device (stop watch or clock). It involves 14 different functional tasks, each scaled from
0-4 based on ability (Stevenson, 2001).
Van Swigchem et al. (2012) explored the possible influence of the Bioness L300® on
balance of community dwelling, chronic stroke patients experiencing foot drop. The study
specifically looked at Thnctional balance, through obstacle avoidance ability, and found subjects
wearing the Bioness L300® avoided obstacles better than when wearing the AFO. Our research
attempted to find similar improvements in functional balance. As the BBS is a reliable tool
when considering this measure in the population at hand it was a reasonable choice to record
such improvements in our subjects (Tong et al., 2006).
Timed Up-and-Go (TUG). The Timed Up and Go (TUG) test is accepted as a reliable
method of quantifying functional mobility. Cheng et al. (2010) used the TUG to assess
functional mobility improvements in patients post-stroke experiencing spasticity, as one of four
components of the Emory Functional Ambulation Profile (EFAP). The TUG test is administered
as follows: Upon hearing the phrase “GO”, the evaluator begins a stop watch, and the participant
rises from a seated position, walks three meters, turns around and returns to the starting seated
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position. Once seated, the evaluator stops the stop watch, and records the time in seconds (Ng &
Hui-Chan, 2009; Cheng et al., 2010). The TUG test is used by the therapists at BRH as a
functional outcome measure to determine improvements in walking velocity and to indicate falls
risk. The TUG test has been accepted as a validated and useful measure for research similar to
ours. Ng & Hui-Chan (2009) used the TUG as an outcome measure when investigating whether
or not the use of TENS (transcutaneous electrical nerve stimulation) would yield meaningful
improvements in gait velocity, walking endurance, and functional mobility in patients who were
at least one-year after theft first (and only) stroke. The 109 participants were split amongst four
conditions: TENS only; TENS + exercise group; the placebo stimulation + exercise group;
control group. The researchers found all interventions yielded reduced TUG scores, (faster time,
indicating more functional abilities), but the TENS + exercise group achieved significantly better
improvements in TUG scores from the second week of the intervention, to the conclusion at the
fourth week.
Modified Ashworth Scale. Researchers investigating improvements in gait parameters
of acute, sub-acute, and chronic stroke patients frequently regard the Modified Ashworth Scale
(MAS) as an exclusion parameter, identi~ring patients who score greater than 2, as ineligible to
participate in the study (Wening, Huskey, Hasso, Aruin, & Rao, 2009; Soloppova, Tihonva,
Grishin & Ivaneko, 2011). However, Wang, Chan, and Tsai, (2000) used the MAS as an
outcome measure when considering the effect of electrical sensory stimulation of the thoraco
lumbar region of the spine (between vertebrate TI 2 and Li) on knee extensor spasticity, of
recovering stroke patients. The ten subjects were an average of 12.5 months post stroke, were
suffering from hemiplegia, and ambulated with assisted devices. The study used the MAS and
recorded EMG activity of the quadriceps and hamstrings to determine improvements in spasticity
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due to a 45-minute, sub-motor electrical stimulation treatment. Significant reductions in
spasticity were found, and agreement between the improved EMG recordings and the improved
MAS scores deemed the scale a sensitive tool when measuring spasticity in post stroke
patients. In our study, the MAS was to be used as a covariant, along with the other outcome
measures.
Patient and therapist survey instruments. Patient satisfaction was evaluated using a
survey designed by the investigators (Appendix A). The mobility portion of the Stroke Specific
Quality of Life Scale was used for several questions. All questions required close-ended
responses from a multiple-choice list and two questions allowed for open-ended responses.
Questions written by the research team addressed patient satisfaction with the device itself
Researchers were interested in learning if patients found the device comfortable, light-weight,
easy to use, safe, and effective in improving their walking while wearing the device. The portion
taken from the Stroke Specific Quality of Life Scale addressed the patients’ perceived functional
abilities while using the device. Therapist survey instruments included all open-ended questions
generated by our research team and also addressed aspects of fhnction and satisfaction
(Appendix B).
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Results
Sample
Investigators recruited six participants with control group (nz 1) and experimental group
(n=4) participants. One participant was removed from our study secondary to determination of
neuropathy and insufficient ROM to for use of Bioness L300® device. Researchers were unable
to recruit a larger sample due to: 1.) changes in patient population at BRH which led to fewer
referrals for patients with stroke; 2.) location changes and scheduling conflicts which restricted
access to use of Zeno Electronic Walkway with PKMAS Software; and, 3.) staffing changes at
BRH which led to additional difficulties in research implementation as recently rotated therapists
were new to the device and less likely to participate.
Table 2 presents demographic information for each participant. Experimental group
(n=4) had a mean age of5l.3 yrs (SD

4.3). Mean length of stay (LOS) was 23.3 days (SD

7.9). Experimental group severity ranged from moderate to severe (moderate [n2], moderate to
severe [n= 1], severe [n1 ]). Only two subjects had increased tone on the MAS at initial
evaluation, but it was not high enough to exclude them. Unfortunately, this measure was not
collected regularly, so there may have been undetected changes in spasticity for any given
subject during the study.
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Table 2.
Subject Demographics
Subject #

Group
Assignment

Gender

~gç
(y~)

Time From
CVA Onset
to
Enrollment
(days)

Length of
$~gy
(days)

Lesion Type

Involved
Side

Severity’

Discharge
Disposition

2

Control

F

51

11

21

Ischemic

L

Minimum

Home with
outpatient
care

3

Experiment

M

48

14

21

Ischemic

R

Moderate

Subacute

4

Experiment

M

55

4

14

Ischemic

L

Moderate

Home with
outpatient

5

Experiment

M

46

15

33

Hemorrhagic

R

Severe

Subacute

6

Experiment

M

56

24

25

Ischemic

L

Severe

Subacute

‘Impairment classification based on the lead investigator’s clinical experience and clinical decision making.
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Subject #2 was the sole patient randomly assigned to control group and presented with
acute non-hemorrhagic infarct of the posterior aspect of the right basal ganglia extending to the
right periventricular space. This subject was discharged to home with outpatient care.
Subject #3 was assigned to the experimental group and presented with left basal ganglion
infarct to the periventricular space. Regional and chronic microvascular changes to right frontal
lobe and chronic infarct in right brainstem were also noted. This subject has a non-specficied
history of neuropathy of left upper extremity and left lower extremity. The patient’s right side
was involved from the stroke. The subject was discharged to subacute care.
Subject #4 was assigned to experimental group and presented with lacunar infarct of right
basal ganglia and posterior limb of internal capsule and discharged to home with outpatient care.
Subject #5 was assigned to experimental group and presented with a large left thalamic
hemorrhage with 5mm mid-line shift requiring a left decompressive hemicraniotomy. Subject
also received a placement of bone flap in abdomen. Subject was discharged to a subacute
rehabilitation facility.
Subject #6 was assigned to experimental group and presented with right middle cerebral
artery watershed infarct with right internal carotid artery occlusion. Subject was discharged to a
subacute rehabilitation facility.
Outcomes
Due to administrative difficulties and time-constraints during clinical practice, not all
outcome measures were collected. Table 3 provides baseline and outcome measurements
excluding Zeno Electronic Walkway with PKMAS Software data. Outcome values for each
patient are provided for initial evaluation, intermediate evaluation(s), and discharge
evaluation. Intermediate evaluation values from the Zeno Electronic Walkway are reported as
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the week one values for all subjects except #5, because data was lost due to a glitch in the
software. For subject #5, the intermediate value with the “device on” was his week two
evaluation. Not all patients had multiple weeks of data due to time-constraints, administrative
issues, or short patient length of stay.
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Table 3.
Patient Outcome Results
Initial Evaluation
Subject # Modified Ashworth
Scale

Intermediate Evaluation(s)
Ambulation Distance

(f~~a
Assistive Device, and
Therapist Assist

Discharge Evaluation

Ten-Meter
Walk Test
(seconds)

P!~
Balance
Scale

Timed Upand-Go
(seconds)

Ten-Meter
Walk Test
(seconds)

~g
Balance
Scale

Timed Upand-Go
(seconds)

Ten-Meter ~
Walk Test Balance
(seconds) Scale

Weekl:30
Week 2: 36

Weekl:55

-

4!

38

-

56

20

78

-

46

13

-

5

-

-

32

83

2

0

90,
Rolling Walker,
Contact Guard

260

23

61

68

3

0

33.
Narrow Base Quad Cane,
Moderate Assist

142

10

140

-

4

1+ (Hip extensors),
1+ (Hip adductors),
2 (Knee flexors)

45,
Wide Based Quad Cane,
Moderate Assist

-

-

22

-

5

1+ (Hip extensors),
13,
I (Hip adductors),
At Hemibar,
1+ (Knee flexors),
Maximal Assist x 2
I (Ankle plantarflexors)

-

-

-

-

6

0

6

-

-

33,
160
Wide Based Quad Cane,
Moderate-Maximum Assist

Weekl:14
Week 2: 27

40

17

Week t: 4
Week 2: 5
Week 3: 3

19

78

Timed Up
and-Go
(seconds)
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Zeno Electronic Walkway with PKMAS Software Results and Analysis. All
sub] ects’ spatio-temporal gait findings were collected by the Zeno Walkway with PKMAS
Software. Experimental subjects’ spatio-temporal findings were statistically analyzed using
Friedman and Wilcoxon analysis for within-subjects comparison. The level of significance
required for quantitative verification of any significant findings wasp

=

.05.

Subjects’ mean gait velocities throughout treatment are presented in Figure 2. All
sub] ects demonstrated increased mean velocity from initial evaluation to discharge with the
device on and with the device off.
Single leg stance mean percentages for the involved lower extremity are presented as a
graph in Figure 3. This variable described the percentage of time during the gait cycle that the
patient spent in single limb support on their involved lower extremity. For experimental subjects
with the device on, a non-parametric Friedman test of differences among repeated measures was
conducted and rendered a CM-square value of 6.0 which was significant, (p.05). A Wilcoxon
Signed-Ranlcs test indicated that Intermediate Evaluation approached statistical significance to be
higher than Initial Evaluation, Z -l .826, pO.O68, and that Discharge Evaluation approached
statistical significance to be higher than Initial Evaluation, Z-1.826,p0.068.
For experimental sub] ects with the device off, a non-parametric Friedman test of
differences among repeated measures was conducted and rendered a CM-square value of 6.5
which was sigfflficant,p.039. A Wilcoxon Signed-Ranks test indicated that Discharge
Evaluation approached statistical significance to be higher than Intermediate Evaluation, Z
l.&26,p0.O68, and that Discharge Evaluation approached statistical significance to be higher
than Initial Evaluation, Z

-

1.826, p0.O68.
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Subject K

Figure 2. Mean Velocity. This figure demonstrates the patient’s mean velocity during their gait
evaluation on the Zeno Electronic Walkway. Each participant made an improvement in their gait
velocity from baseline to discharge.
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Figure 3. Single Leg Stance Mean Percentage, Involved Lower Extremity. This graph
demonstrates each patient had an increase in the average percentage of time they spent in single
limb support on their involved lower extremity during their rehabilitation stay in both the device
on and off situations.
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The percent of gait cycle in stance phase (stance mean percentage) for the uninvolved
lower extremity is presented as a graph in Figure 4. For experimental subjects with the device on,
a non-parametric Friedman test of differences among repeated measures was conducted and
rendered a Chi-square value of 6.0 which was significant, (p.05). A Wilcoxon Signed-Ranks
test indicated that Intermediate Evaluation approached statistical significance to be lower than
Initial Evaluation, Z-1.826,p=0.068, and that Discharge Evaluation approached statistical
significance to be lower than Initial Evaluation, Z=-1.826,p=0.068.
Mean step length for the uninvolved lower extremity is presented in Figure 5. For
experimental subjects with the device off, a non-parametric Friedman test of differences among
repeated measures was conducted and rendered a CM-square value of 8.0 which was significant,
(p=.0 18). A Wilcoxon Signed-Ranks test indicated that Intermediate Evaluation approached
statistical significance to be higher than Initial Evaluation, Z=’-1.826, p=0.068, Discharge
approached statistical significance to be higher than Intermediate Evaluation, Z =-l .826,

pO.O68, and that Discharge Evaluation approached statistical significance to be higher than
Initial Evaluation, Z

-

1.826, pO.O68.

Mean stride length values for the involved lower extremity are presented as a graph in
Figure 6. For experimental subjects with the device on, a non-parametric Friedman test of
differences among repeated measures was conducted and rendered a Chi-square value of 6.0
which was significant, (p=.05). A Wilcoxon Signed-Ranks test indicated that Intermediate
Evaluation approached statistical significance to be higher than Initial Evaluation, Z =-l .826,
pO.O68, and that Discharge Evaluation approached statistical significance to be higher than
Initial Evaluation, Z

-

1.826, pO.O68.
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Figure 4. Stance Mean Percentage, Uninvolved Lower Extremity. This graph displays the
percentage of time the patient spent in stance phase on their uninvolved lower extremity. Each
patient demonstrated a decrease in this percentage.

32

bter

Evaluation

S0000

~ Saseline

50000~
0)
C
a’
-J

C Intermediate

4OOO~

C

30.000

0

o Discharge

a’
-C
it

0

20.000

at

10000-

once-

-10.000- __________________________________________________
60.000-

5o.0c~
C

40,000

0,

S
-C

30,000

~1

C,

a’

0

20,000

z

10,0000,00&
.-1o.000-

Subject #

Figure

5.

length

with the

Mean Step

patient

Uninvolved Lower Extremity.

uninvolved lower extremity on each trial.

length improved in

the

Length,

did not

the

device on

and off situations.

This graph

The

displays

the

average step

uninvolved lower extremity step

Negative mean step lengths occurred when

step beyond their opposite leg.

33

Evaluation

100.000-

£
0,
C
4,
—I
S
-U

ao.ooo

z
0
0

60.00W

I

40.00W
C
Ci

20.000
0.000
100.000

~

60.000

C,
4~

0

0,

C
S
-‘

~ Base~ne
~ Intermediate
C Discharge

S
-C

60000

0

‘a

S

-o

0

40.000
C

20.000~
0.000~~~

Subject #

Figure 6. Mean Stride Length, Involved Lower Extremity. This displays the average stride
length with the involved lower extremity during the gait evaluation. Each patient improved this
value from baseline to discharge.
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Terminal double limb support mean percentage coefficient of variations for the
uninvolved lower extremity are presented as a graph in Figure 7. This variable refers to the
consistency throughout gait for the amount of time spent with the uninvolved lower extremity in
push off and the involved lower extremity in heel strike. A lower value in this variable would
indicate the patient is becoming more consistent in this phase of gait. For experimental subjects
with the device on, a non-parametric Friedman test of differences among repeated measures was
conducted and rendered a CM-square value of 6.0 which was significant, (p=.05). A Wilcoxon
Signed-Ranics test indicated that Intermediate Evaluation approached statistical significance to be
lower than Initial Evaluation, Z

-

1.826, pO.068, and that Discharge Evaluation approached

statistical significance to be lower than Initial Evaluation, Z =-1 .826, p=O.O68.
Terminal double limb support mean percentages for the involved lower extremity are
presented as a graph in Figure 8. This variable indicates the amount of time the patient spends
with their involved lower extremity in push-off and uninvolved lower extremity in heel strike. A
lower value in this variable would indicate that the patient is taking less time to transition from
terminal stance into swing phase on their involved lower extremity. The results were the same
for the device on and off situations, a non-parametric Friedman test of differences among
repeated measures was conducted and rendered a Chi-square value of 6.5 which was significant,
(p=.039). In both situations, a Wilcoxon Signed-Ranks test indicated that Intermediate
Evaluation approached statistical significance to be lower than Initial Evaluation, Z -l .826,

p=O.O68, and that Discharge Evaluation approached statistical significance to be lower than
Initial Evaluation, Z =-1 .826, pO.O68.
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Figure 7. Terminal Double Support Mean Percentage Coefficient of Variation, Uninvolved
Lower Extremity. This graph displays the coefficients of variation for the terminal double
support time mean percentage. This variable improved in the device on condition, but not in the
device off condition.
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Figure 8. Terminal Double Support Mean Percentage, Involved Lower Extremity. This graph
displays the average percentage of time the subject spent in push-off on their involved lower
extremity. This value decreased from baseline to discharge in both the device on and off
conditions.
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Patient Survey Results. Patient and therapist surveys were completed for subjects #2,
#4, and #5. Subjects #3 and #6 did not have patient or therapist survey results completed due to
time-constraints and administrative difficulties. Control findings are represented solely by
subject #2’s responses. Experimental findings are represented by responses from subjects #4 and
#5.
Responses to patient survey questions #2-6 pertain to use of the Bioness L300® device or
other dorsiflexion assist specifically in the context of gait. Control subject #2 reported the best
possible review of the AFO of figure-8 wrapped elastic bandage along all questions and
dimensions. The patient found the device comfortable, light-weight, easy to use, safe, and
helpful within the context of gait and reported on the helpfulness of the device that it “helps me
to walk better, foot not as heavy”.
Subject #4 in the experiment group also reported the best possible review of the Bioness
L300® along all questions/dimensions and thus reported that they found the device comfortable,
light-weight, easy to use, safe, and helpful within the context of gait. Subject #4 also reported,
“There appeared to be no safety issues re: my device while using it. The machine was calibrated
and customized for my use.” and, “[the] device helped prevent drag in my step. Preventing me
from tripping”. Subject #5 in the experiment group reported the best possible review of the
Bioness L300® along all questions/dimensions except for question #4 regarding ease of use, for
which they were neutral.
Responses to patient survey questions 7-12 pertain to general mobility (questions were
adapted from the Stroke Specific Quality of Life scale). Control subject #2 reported “no trouble
at all” (the best possible review) for all questions and mobility tasks utilizing the AFO or figure
8 wrapped elastic bandage.
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Experimental subject #4 reported “no trouble at all” for all questions and mobility tasks
utilizing the Bioness L300® device. Experimental subject #5, however, reported varying levels
of difficulty with mobility tasks while using the Bioness L300® device indicating “some
trouble” with gait, “some trouble” with fatigue, “a little trouble” with standing, and “a little
trouble” with sit-to-stand.
Therapist Survey Results. Therapist surveys for use of the AFO or flgure-8 wrapped
elastic bandage are limited to Subject #2. The therapist reported that positioning of the foot was
the best aspect for use of the conventional dorsiflexion devices with Subject #2 but did not
provide more detail. The therapist also reported that application of the wrap or brace prior to
ambulation was the worst aspect of the AFO or figure-of-eight wrap with Subject #2. The
therapist reported that the control devices were easy to don and doff for Subject #2 and that the
devices improved Subject #2’s foot clearance through the swing phase of gait. Overall, the
therapist reported satisfaction with Subject #2’s outcomes using the conventional dorsiflexion
devices and noted that Subject #2 was able to ambulate safely with the AFO or figure-8 wrapped
elastic bandage dorsiflexion assist.
Therapist surveys regarding use of the Bioness L300® experimental device with a
specific patient are available for subjects #4 and #5. Subject #4’s therapist survey is incomplete.
Subject #4’s therapist reported consistency of foot placement and clearance as the best aspect of
the Bioness L300® device and set-up time as the worst aspect. Overall, the therapist reported
satisfaction with Subject #4’s outcomes using the Bioness L300® device.
Subject #5’s therapist reported that assistance with dorsiflexion to improve lower
extremity clearance was the Bioness L300® device’s best aspect for use with Subject #5 and that
difficulty with sequencing and patient behavior was the worst aspect (no further clarification was
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provided). The therapist noted that the Bioness L300® device was not easy to don and doff on
Subject #5 and that Subject #5’s impulsivity made the device difficult to use. The therapist also
reported that the Bioness L300® required increased time and effort for set-up. Overall, the
therapist reported satisfaction with Subject #5’s outcomes using the Bioness L300® and reported
that benefits of the Bioness L300® device include increased sensory feedback.
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Discussion
The original purpose of this study was to determine whether FES, when used as an
adjunct to conventional therapy in the acute stages of rehabilitation following a stroke, provides
greater functional improvements in an individual’s gait, when compared to the use of a
temporary dorsiflexion assist device such as a figure-8 wrapped elastic bandage or an AFO.
Logistical problems, however, limited the scope of this study, converting this study from a
prospective within- and between-subjects design to a preliminary case series that examined the
feasibility and potential benefits of incorporating FES into acute stroke rehabilitation.
During the course of this study, many of the stroke patients admitted to BRJ4 were
medically complex and did not meet the inclusion criterion of this study, limiting the number of
participants. Additionally, with a limited sample size, the coin-toss assigned virtually all
participants to the experimental FES group, preventing a true comparison of FES to the use of
temporary dorsiflexion assist device. Other logistical complications included staffing changes
that resulted in inconsistent administration of the Berg Balance Scale (BBS), Timed Up and Go,
and 10-Meter Walk Tests, and frequent changes to the location of the Zeno Electronic Walkway,
made it difficult to coordinate patients’ treatment sessions and data collection. Furthermore, a
glitch in recording on the Zeno Walkway for subject #5 led to a missing trial on week 1 with the
“device on”, necessitating the change to an “intermediate” data reference.
Despite the logistical problems encountered during this study, we demonstrated that gait
training with the Bioness L300® FES system can be integrated into an acute rehabilitation
protocol without adverse effects to the patient. The therapists commented on its ease of use and
the patients felt comfortable using it for gait training. Our results showed improvement in gait
quality that would indicate the device may have some effect on recovery. The Friedman test,
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comparing the measurements among the initial evaluation, intermediate assessment and
discharge, found a significant improvement in most gait parameters in all sub] ects, in both the
device on and device off conditions. Without a control group, it is uncertain whether the
improvements derive from the use of the Bioness L300®, or are a result of normal recovery.
Adding to this uncertainty is the fact that Subject #2 only used a temporary dorsiflexion assist
device, and also demonstrated significant improvement in gait parameters during the course of
this study. Furthermore, the Wilcoxon tests did not produce significant results on any of the gait
parameters, indicating the time frame (between initial evaluation and intermediate evaluation or
intermediate evaluation and discharge) of greatest potential for gains is still unclear.
Stride Length and Step Length
Sub] ects displayed a significantly improved stride length of the involved extremity with
the device on at discharge. An improved stride length indicates better foot clearance as well a
better heel strike. The device off condition, however, did not yield the same results. This
indicates that having the FES device on can improve stride length. We also documented a
statistically significantly improved step length of the uninvolved side. This indicates individuals
became more confident weight bearing on their involved side, with the device off, to make a
greater advancement of the contralateral lower extremity. Unfortunately, we cannot contribute
this result to the patient’s recovery or to use of the device itself.
Our results are similar to Sabut et al., (2010), who found statistically significant
improvements in step length in the chronic stroke population with use of the FES device. In that
study, chronic stroke patients who were three months post-stroke and community ambulators
participated in a 12-week intensive training program. Pre and post-test measures were
taken. The experimental group, using an FES device, displayed a significant improvement in
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step length from pre to post-test. These improvements were significantly greater than the step
length improvements in the control group, which received conventional rehabilitation.3
Our results also correlate with Cheng et al., (2010). Like Cheng et al., our finding of
improved step length on the uninvolved side infers a more equal gait pattern between the two
lower extremities, although our fmding was with device off and Cheng et al. ‘ s findings were
with the device on. The Cheng et al., (2010) study examined the effects of electrical stimulation
at the tibialis anterior during balance activities (on the balance master), rather than its use during
ambulation, as our study did. The primary focus of the study was the impact on the electrical
stimulation on the spasticity of the plantarfiexors. Still, the study used improvement in gait as an
outcome measure, and thus comparisons can be made. Cheng et al. (2010), found the ratio of
asymmetrical spatial characteristics of gait significantly improved in the experimental group
(using FES), but not the control group (not using FES), when subjects were compared to
themselves at baseline to post-treatment, indicating that the experimental subjects gait became
more equivalent from the involved to uninvolved lower extremity.
Coefficient of Variation: Normalization of Gait Patterns
Our research considered the overall temporal qualities of gait (initial double support as a
percentage of gait cycle; terminal double support as a percentage of the gait cycle, time spent in
single support, as a percentage of gait cycle etc.) individually, and found significant
improvement in the terminal double stance of the uninvolved limb as the coefficient of variation
decreased.4 This time of terminal double support (theoretically) refers to the time both lower
extremities are in contact with ground, while the reference limb (the uninvolved limb) is

~ Sabut et al., (2010), did not define “conventional” therapy in their study, so it is unclear
whether a temporary assist device was used.
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approaching push off. This gives corresponding information of the involved limb, as it is
simultaneously (theoretically) at initial contact or heel strike. An improvement in the coefficient
of variation indicates that the time participants spent in terminal double limb support became
more consistent in terms of temporal parameters, indicating their gait consistency
improved. When evaluating the coefficients of variation for this variable, we found with the
device on, subjects spent a more consistent amount of time in terminal double stance of the
uninvolved lower extremity, which was not as consistent with the device off. This indicates the
time the uninvolved limb spent in push off consistently decreased, and the involved limb
required a consistent amount of time (and consistently less) to achieve a successful heel strike of
the uninvolved limb. This fmding is not reported individually, but as an overall temporal
asymmetrical ratio between the affected and non-affected in the Cheng et al (2010) study. Our
study describes an improvement in this variable, which would correlate to an improvement the
ratio reference by Cheng et al (2010). In contrast to our study, however, Cheng et al. (2010) did
not find statistically significant improvements or normalization in temporal asymmetrical ratio
between the affected and non-affected sides in the experimental group. On the other hand,
Dunning et al. (2009), conducted a case series (n=2) using the Bioness L300® device in acute
rehabilitation and reported findings in line with ours in one subject, noting a general decrease in
coefficients of variation for several variables during gait, insisting that this subject’s gait became
more consistent through the course of their therapy.
Single Limb Support Time and Terminal Double Support Time
In our research, we saw an improvement in single limb support time and decrease in
terminal double support time (as a percentage of the entire gait cycle) in the device on
condition. The device off condition also displayed a significant improvement in these variables
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as well. With such a small sample size, it is difficult to determine whether the improvements
came from the use of the device, or the natural recovery that occurs following a stroke. The
improvement in the coefficient of variation is a significant contribution to the use of the Bioness
L300® device in acute rehabilitation because a more consistent gait pattern will malce the
physical therapist and patient more efficient in therapy. If the patient can train with a more
efficient gait, we can assume the patient may be able to make more gains in those first three
months of recovery.
We expected a similar change in the device on and off situations to support that training
with the device can develop neuroplasticity, however some gait variables demonstrated
improvements only in the device on situation, and without a control group we cannot determine
which improvements were from the device and which were from general recovery.
Impact of Stroke Severity on Outcomes
Our results appear to indicate that the most severely impaired participants seemed to
benefit the most from the FES device. This was seen specifically when single leg stance mean
percent coefficient of variation of the uninvolved lower extremity was considered. The time
spent in single leg stance of the uninvolved lower extremity, corresponds to the swing phase of
the involved lower extremity. The subject with the most severe impairment, subject #5, showed
the greatest decrease in gait variation while using the device compared to device off at discharge.
This finding is comparable to the findings of Dunning et al. (2009). Dunning et al. (2009)
examined two subjects. Baseline measurements show that Dunning et al.’s (2009) second
subject was more impaired than subject number one, particularly in terms of endurance.
Dunning et al. (2009) found the differences between the device off and device on condition to be
less dramatic, after just seven days of using the device on subject number one, after which time
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the researchers chose to discontinue use of the device. In the second subject, the differences still
occurred at week four, and warranted the continued use of the device. Also interestingly, subject
number five in our study, as well as both subjects in the Dunning et al (2009), had sustained a
hemorrhagic stroke. The rest of our subjects sustained ischemic stroke. These findings begin to
highlight the need for larger experiments, with better control over severity and type of stroke, in
order to pinpoint which particular population may benefit most from this adjunct to therapy.
Berg Balance Scale (BBS) Outcomes
While this study was not able to obtain reliable statistical data for the BBS for all
participants, two subjects, Subject #2 and Subject #3, were assessed using the BBS allowing for
an anecdotal examination of the fmdings. Subject #2 (control), who had minimal disability, was
assessed with the BBS at initial evaluation, week one, week two, and discharge. Over the course
of the study, subject #2 showed a steady improvement in balance, however it cannot be
determined if this improvement is due to the use of AFO or spontaneous recovery of function.
Subject #3 (experimental), ranked at a level of moderate disability showed a 7-point decrease in
the BBS, from week two to discharge. It is unclear what caused this decrease.
Patient Preference
This study considered the subjects’ preference of his or her device. We provided
subjects with surveys, addressing concerns like comfort, lightweight feeling of the device, ease
of use during gait, and safety. We used an adaptation of the mobility section of the Stroke
Specific Quality of Life Scale, addressing trouble walking, balance while bending over, stair
negotiation, increased need to stop and rest, difficulty standing, and difficulty transferring from
sit to stand.
Because of logistical limitations in supervising survey administration, we did not obtain a
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completed survey from all subjects. A total of three respondents (out of a total of five
participating subjects) participated in the survey. Two of the three subjects that completed
surveys used the Bioness L300®, and both agreed the device was easy to use during gait
training. The third subject who completed the survey was the control, who used the elastic wrap
bandage device. All three subjects agreed the device they used was comfortable, and lightweight
and safe, and helped with walking, which reports were similar to Dunning et al.’s (2009) first
subject, who had a similar opinion, and stated that he liked the stimulation because it helped him
walk be keeping his foot up instead of dragging. Interestingly, however, subject #2, who was
randomly assigned to the control group by coin toss, stated she would have deferred participation
in the study if she was put in the experimental due to fear of using the FES device, indicating that
not all patients may prefer FES or fmd it to be preferable to a figure-8 wrapped elastic bandage.
Future Research
Dunning et al. (2009) conducted exploratory research into this topic, which was used to
model the methods for this case series. We were able to expand the sample size to five subjects,
one who stood as a control subject, who did not use the Bioness L300® device; however,
because of our small sample size, we were unable to provide statistical comparisons between the
control and experimental conditions. Similar to Dunning et al. (2009), our five subjects trained
between assessment times with their designated device, and subjects were assessed in outcome
measures both with and without the chosen device. Unlike Dunning et al. (2009), however, we
only required that the subjects use the device a minimum of three sessions per week, compared
to the five days a week used by Dunning et al. (2009). Unfortunately, our study was unable to
control for severity and demonstrate a significant difference between groups.
Future research could look to explore training with this device versus a control. This
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would allow inference into whether the patient improved by recovery or via training. Our
qualitative data led us to think that there may be a difference in usefulness of this device
depending on the stroke severity. Future research may look into correlating severity with effects
of the device.
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Conclusion
Foot drop is common impairment post stroke that leads to increased falls risk for
patients. The Bioness L300® device’s effectiveness has been studied extensively in chronic
stroke populations but its use in acute populations has been limited. We hypothesized that the
Bioness L3 OO® device may be useful in acute stroke rehabilitation as early ambulation gains are
critical and the device may help normalize gait and increase corticospinal connections. While
we were unable to make statistical comparisons of the Bioness L300® device against
conventional dorsiflexion assist devices such as an AFO or figure-8 wrapped elastic bandage, our
findings suggest that the Bioness L300® is feasible for study in acute in-patient
rehabilitation. Future research should include a greater control sample to isolate the effect of
Bioness L300® from spontaneous stroke recovery and compare its effectiveness against
conventional devices.
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Appendix
Appendix A
Research Patient ID#

Patient Survey Instrument
For all questions, please select only one answer. Please askfor clar~fication on any
questions you are unsure about.
1.) Which device did you use in gait-training during treatment?
a.) Ness300 only
b.) Combination ofNess300 and another device
c.) Foot-wrap only
d.) Brace only
e.) Combination of foot-wrap and brace
If answer to question] is a or Li, questions 2-12 refer only to treatment utilizing the Ness300
device.
If answer to question] is c, d, questions 2-12 refer only to either the foot-wrap or brace
device utilized in treatment.
Ifanswer to question] is e, questions 2-]2 refer only to the foot-wrap device utilized in
treatment.
2.) The device used in gait training was comfortable.
a.) Agree
b.) Neutral
c.) Disagree
3.) The device used in gait training was light-weight.
a.) Agree
b.) Neutral
c.) Disagree
4.) The device used in gait training was easy-to-use.
a.) Agree
b.) Neutral
c.) Disagree
5.) Did you feel safe using the device:
a.) Yes
50

bjNo
Please
explain:_____

6.) Do you think the device helped your walking efficiency?
a.) Yes
b.)No
Please
explain:

The remaining questions 7 12 are adaptedfrom the mobility section of the Stroke Spec~fic
Quality ofL~fe Scale. Each item shall be scored with the following key:
-

1
2
3
4
5

—

—

—

—

—

couldn’t do it at all;
a lot of trouble
some trouble
a little trouble
no trouble at all

If an activity in a particular question was not performed with the device, please skip that
question or leave blank.
7.) While wearing the device, did you have trouble walking?

____

8.) While wearing the device, did you lose your balance when bending over to or reaching
for something?
____

9.) While wearing the device, did you have trouble climbing stairs?
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10.) While wearing the device, did you have to stop and rest more than you would like when
walking or using a wheelchair?
11.) While wearing the device, did you have trouble with standing?

_____

12.) While wearing the device, did you have trouble getting out of a chair?

52

Appendix B
Research Patient ID#_________________________
Therapist Survey Instrument
1.) For this patient, which device did you use in gait-training during treatment?
a.) Ness300 only
b.) Combination ofNess300 and another device
c.) Foot-wrap only
d.) Brace only
e.) Combination of foot-wrap and brace
If answer to question 1 is a or b, questions 2-6 refer only to treatment utilizing the Ness300
device.
Ifanswer to question 1 is c, ci, questions 2-6 refer only to either the foot-wrap or brace
device utilized in treatment.
Ifanswer to question I is e, questions 2-6 refer only to the foot-wrap device utilized in
treatment.
2.) For this patient, what was the best aspect of the device?
Please explain:

3.) For this patient, what was the worst aspect of the device?
Please explain:

4.) Were you satisfied with this patient’s outcome?
Please explain:
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5.) For this patient, was the device easy to don and doff?
Please explain:

6.) What perceived benefits did the device confer for this patient? Please explain:
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